Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Molecular differences between tumor endothelial cells from low- and high-grade gliomas

ABSTRACT: Molecular differences between tumor endothelial cells from low- and high-grade gliomas

PROVIDER: PRJNA991575 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR25152537_1.fastq.gz	Fastqsanger.gz
	SRR25152537_2.fastq.gz	Fastqsanger.gz
	SRR25152538_1.fastq.gz	Fastqsanger.gz
	SRR25152538_2.fastq.gz	Fastqsanger.gz
	SRR25152539_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 72

Similar Datasets

Genomic aberrations of high-grade and low-grade gliomas from Chinese patients

Project description:We carried out the analyses of chromosome variations between low-grade and high-grade gliomas in Chinese population. We found out the differences in chromosomes, cytobands, genes, pathways and GO functions. To identify the glioma tissue-specific genomic alterations and compare the genomic variations between low-grade and high-grade gliomas.

2015-01-03 | E-GEOD-34888 | biostudies-arrayexpress

Low grade gliomas

Project description:Categorisation of LGGs related to their lesion site (infratentorial vs. supratentorial) 40 Low grade gliomas samples

2013-09-21 | E-GEOD-28238 | biostudies-arrayexpress

Genomic aberrations of high-grade and low-grade gliomas from Chinese patients

2015-01-03 | GSE34888 | GEO

Low grade gliomas subtype analysis

Project description:Low grade gliomas subtype analysis

| PRJEB9786 | ENA

Differential transcriptome between low and high-grade gliomas

Project description:Glioblastoma (GB) is the most aggressive form of glioma and is characterized by a poor prognosis and high recurrence, despite intensive clinical interventions. To retrieve the key factors underlying the high malignancy of GB, we performed differential expression analysis between low and high-grade gliomas by using RNA-seq.

2021-11-30 | GSE185861 | GEO

Differential transcriptome between low and high-grade gliomas

Project description:Differential transcriptome between low and high-grade gliomas

| PRJNA771039 | ENA

Differential DNA methylome between low and high-grade gliomas

Project description:Glioblastoma (GB) is the most aggressive form of glioma and is characterized by a poor prognosis and high recurrence, despite intensive clinical interventions. To retrieve the key factors underlying the high malignancy of GB, we performed differential methylation analysis between low and high-grade gliomas by using Infinium MethylationEPIC beadchips.

2020-12-31 | GSE147391 | GEO

Differential DNA methylome between low and high-grade gliomas

Project description:Differential DNA methylome between low and high-grade gliomas

| PRJNA614473 | ENA

Genomic Analysis of Pediatric low-grade gliomas

Project description:Genomic Analysis of Pediatric low-grade gliomas

| PRJNA198059 | ENA

Low grade gliomas subtype analysis

Project description:Low grade gliomas (LGG; WHO grade 2 astrocytomas, oligodendrogliomas and oligoastrocytomas) account for about 25% of diffuse gliomas. Most occur in young adults between the ages of 30 and 45 years, and are usually only diagnosed after a seizure. In general, they can be characterised by a long period of continuous slow growth, followed by malignant transformation that will be the cause of death up to 25 years after onset. However, there is a significant number of patients for whom malignant progression is more rapid, with mortality observed within 5 years. This suggests that, as with other tumour types, there may be different subtypes of LGG with specific prognosis. It follows that being able to identify these subtypes may permit better patient stratification and aid targeted treatments. Until recently, our understanding of the variables involved in patient prognosis included the type of tumour oligodendroglial tumours indicate better prognosis than oligoastrocytic or astrocytic and presence of the 1p-19q co-deletion. In addition, the recent discovery of mutations in IDH1&2 in the majority of LGGs provided another means of stratifying patients, while offering an important insight into their biology. However, we still understand very little of the biology behind the genesis and progression of the 70-80% of LGG that bear IDH1&2 mutations, let alone the remaining IDH wild-type tumours.

2015-07-07 | E-MTAB-3708 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data